As we reach the end of June, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI. To subscribe to BPIQ companies Learn more here.
Table 1. BPIQ company weekly/monthly moves and YTD moves
Category | Weekly Move 6/27-7/1 | YTD Move |
|---|---|---|
All BPIQ Companies | -0.89% | -45.82% |
CAR-T Companies | -1.71% | -53.85% |
Gene Editing Companies | -4.73% | -52.58% |
XBI | -0.67% | -31.64% |
See the biggest moves from last week below:
Don't miss upcoming catalysts.. Get our weekly Catalyst Watchlist Free!
*We never send you spam - unsubscribe anytime
Highlights for the week
Biggest positive move
#EVFM +146% Evofem Reaches Agreement with One of the Largest Pharmacy Benefit Managers in the U.S. for Access to Phexxi®
#IFRX +84.62% InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19
Biggest negative move
#TALS -70.92% Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update
Additional weekly big moves
#AXSM +66.2% Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders
#DBTX +65.5% Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy.
#EPZM +55.8% Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology. source
#ENDP +54.1% Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants with Adhesive Capsulitis of the Shoulder. source
#KZR +53.8% Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis.
#STRO +21.5% Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs).
#GRAY +19.5% Graybug Announces Review of Strategic Alternatives.
#NVAX +10.6% Novavax Statement on Prototype Vaccine’s Broad Immune Responses and Accelerated Focus on Omicron BA.4/5 as Recommended by the FDA. source Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC.
#SPRO -11.7% Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application
#RLAY -13.3% Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event.
#NUVB -16% Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors.
#HRTX -20% Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability.
#AMRN -25% REDUCE-IT EXPLORATORY POST HOC BIOMARKER SUB-ANALYSIS SHOWS RELATIVELY SMALL CHANGES IN INFLAMMATORY MARKERS BETWEEN ICOSAPENT ETHYL AND PLACEBO.
#ICVX -27.1% Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV.
#CDAK -33.7% Codiak Provides Platform-Validating Clinical Update and Data from Phase 1 Trials of exoSTING™ and exoIL-12™.
#ALRN -40% Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer.
#ENOB -42.0%
#NMTR -42.1% 9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome.
#ANGN -42.9% ANGION ANNOUNCES DISCONTINUATION OF PHASE 2 TRIAL OF ANG-3070 IN PATIENTS WITH PRIMARY PROTEINURIC KIDNEY DISEASE
#AGRX -44.4% AGILE THERAPEUTICS ANNOUNCES PRICING OF $24 MILLION UPSIZED PUBLIC OFFERING. source
Highlights for next week
To see next week's Big Movers HERE, subscribe. Learn more here.
$ANEB ANEB-001 data readout
$HZNP KRYSTEXXA PDUFA
See our new July PDUFA list
See our Big Movers post to learn about upcoming Movers throughout July and PDUFAs, after subscribing. Learn more here.
Comments